Notably, 2 out of 3 patients with anti-thyroglobulin auto-antibodies developed a clinically significant thyroiditis requiring levothyroxine therapy after 1.1 and 2.8 years of ropegIFNα2b therapy, respectively. This evidence concerns the gene TG and thyroid gland disorder.